XML 48 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Stock-based Compensation

Stock Incentive Plan
The Company has a stock incentive plan, the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the "Plan") that provides for the granting of stock options, restricted stock units ("RSUs"), performance stock options ("PSOs"), and other stock-based awards to eligible individuals on the terms and subject to the conditions set forth in the Plan. There were no significant modifications to the Plan during the three months ended March 31, 2020 or 2019.
Stock-based compensation expense included in the condensed consolidated statements of comprehensive loss was $3.8 million, and $1.7 million for the three months ended March 31, 2020 and 2019, respectively.

The following table summarizes the activity for stock options, RSUs and PSOs for the three months ended March 31, 2020 (in thousands):
 
Stock Options
 
RSUs
 
PSOs
Equity awards outstanding, beginning of year
5,901

 
58

 
837
   Changes during the year:
 
 
 
 
 
   Granted
1,429

 
100

 
—

   Exercised
(7
)
 
—

 
—

   Expired or forfeited
(281
)
 
—

 
(153
)
Equity awards outstanding, end of period
7,042

 
158

 
684

    
As of March 31, 2020, total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized were as follows ($ in thousands):
 
Stock Options
 
RSUs
 
PSOs
Unrecognized compensation cost
$
47,499

 
$
308

 
$
4,644

Expected weighted-average period in years of compensation cost to be recognized
3.1

 
1.9

 
0.7